SPOTLIGHT -
Dr. Emens on Immune-Related Adverse Events in Ovarian Cancer
Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.
Read More
Dr. Emens on Combining Checkpoint Inhibitors With PARP Inhibitors in Ovarian Cancer
Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.
Dr. Emens on the Future of Immunotherapy in Ovarian Cancer
Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
